[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623771":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":25,"interventions":53,"overallOfficials":70,"centralContacts":74,"locations":80,"responsibleParty":97,"collaborators":13,"id":99,"slug":13,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":13,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":13,"enrollmentInfo":107,"targetDuration":13,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":83,"whyStopped":13,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of study eyes with elimination of collarettes","Percentage of study eyes that had eyelash collarettes due to Demodex blepharitis at the onset of treatment who demonstrate absence of collarettes after 6 weeks of treatment","6 weeks",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"QUADRUPLE",[21,22,23,24],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[26,32,37,42,47],{"label":27,"type":28,"description":29,"interventionNames":30},"GLK-321 low dose BID","EXPERIMENTAL","Low dose of GLK-321 administered twice daily (BID) to both eyes",[31],"Drug: GLK-321 low dose BID",{"label":33,"type":28,"description":34,"interventionNames":35},"GLK-321 mid dose BID","Mid dose of GLK-321 administered twice daily (BID) to both eyes",[36],"Drug: GLK-321 mid dose BID",{"label":38,"type":28,"description":39,"interventionNames":40},"GLK-321 high dose BID","High dose of GLK-321 administered twice daily (BID) to both eyes",[41],"Drug: GLK-321 high dose BID",{"label":43,"type":28,"description":44,"interventionNames":45},"GLK-321 high dose QD","High dose of GLK-321 administered once daily (QD) to both eyes",[46],"Drug: GLK-321 high dose QD",{"label":48,"type":49,"description":50,"interventionNames":51},"Placebo BID","PLACEBO_COMPARATOR","Placebo administered twice daily (BID) to both eyes",[52],"Drug: Placebo BID",[54,58,61,64,67],{"type":55,"name":27,"description":56,"armGroupLabels":57,"otherNames":13},"DRUG","Twice daily administration of low dose GLK-321 to both eyes",[27],{"type":55,"name":33,"description":59,"armGroupLabels":60,"otherNames":13},"Twice daily administration of mid dose GLK-321 to both eyes",[33],{"type":55,"name":38,"description":62,"armGroupLabels":63,"otherNames":13},"Twice daily administration of high dose GLK-321 to both eyes",[38],{"type":55,"name":43,"description":65,"armGroupLabels":66,"otherNames":13},"Once daily administration of high dose GLK-321 to both eyes",[43],{"type":55,"name":48,"description":68,"armGroupLabels":69,"otherNames":13},"Twice daily administration of placebo to both eyes",[48],[71],{"name":72,"affiliation":5,"role":73},"Study Director, MD","STUDY_DIRECTOR",[75],{"name":76,"role":77,"phone":78,"phoneExt":13,"email":79},"Study Manager","CONTACT","949-739-8749","ClinicalResearch@Glaukos.com",[81],{"facility":82,"status":83,"city":84,"state":85,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":94,"contacts":95},"Glaukos Clinical Study Site","RECRUITING","Newport Beach","California","92663","United States","US",{"type":90,"coordinates":91},"Point",[92,93],-117.92895,33.61891,{"lat":93,"lon":92},[96],{"name":76,"role":77,"phone":78,"phoneExt":13,"email":79},{"type":98,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100623771",false,"NCT07400965","Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","Inclusion Criteria:\n\n* Signs of Demodex blepharitis in at least one eye\n* Best Spectacle Corrected Visual Acuity (BSCVA) of 20\u002F80 Snellen or better in each eye\n\nExclusion Criteria:\n\n* Presence of eczema or dermatitis in the ocular region of either eye\n* Use of lid hygiene products within 14 days of Screening\n* Active ocular infection or inflammation, other than blepharitis, in either eye at Screening\n* Women who are pregnant, planning a pregnancy, or nursing\n* Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial","ALL","18 Years",{"count":108,"type":109},250,"ESTIMATED","INTERVENTIONAL",[112],"PHASE2","This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.",[115],"Demodex Blepharitis",[117],"demodex blepharitis","2026-02-24",{"date":120,"type":121},"2026-02-27","ACTUAL",{"date":123,"type":121},"2025-12-05",{"date":125,"type":109},"2026-11",{"name":5,"class":6},1]